Lupberger J, Croonenborghs T, Suarez AAR, et al. Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development. Gastroenterology. 2019;157(2):537-551.e9. doi:10.1053/j.gastro.2019.04.003
Dolciami D, Gargaro M, Cerra B, et al. Binding Mode and Structure-Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist. ChemMedChem. 2018;13(3):270-279. doi:10.1002/cmdc.201700669
Liu H, Golji J, Brodeur LK, et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat Med. 2019;25(1):95-102. doi:10.1038/s41591-018-0302-5
Shao W, Mishina YM, Feng Y, et al. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. Cancer Res. 2018;78(6):1537-1548. doi:10.1158/0008-5472.CAN-17-2033
Archer TC, Ehrenberger T, Mundt F, et al. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2018;34(3):396-410.e8. doi:10.1016/j.ccell.2018.08.004
Malone CF, Stegmaier K. Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma. Cancer Cell. 2017;32(3):271-273. doi:10.1016/j.ccell.2017.08.011
Suen KM, Lin CC, Seiler C, et al. Phosphorylation of threonine residues on Shc promotes ligand binding and mediates crosstalk between MAPK and Akt pathways in breast cancer cells. Int J Biochem Cell Biol. 2018;94:89-97. doi:10.1016/j.biocel.2017.11.014
Iniguez AB, Alexe G, Wang EJ, et al. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 2018;34(6):922-938.e7. doi:10.1016/j.ccell.2018.11.005
Krug K, Mertins P, Zhang B, et al. A Curated Resource for Phosphosite-specific Signature Analysis. Mol Cell Proteomics. 2019;18(3):576-593. doi:10.1074/mcp.TIR118.000943
Price C, Gill S, Ho ZV, et al. Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. Cancer Res. 2019;79(10):2564-2579. doi:10.1158/0008-5472.CAN-18-2674